Germs such as bacteria develop the ability to overcome the medicines designed to kill them, which limits our ability to successfully treat bacterial infections and leads to millions of additional deaths worldwide each year. Tuberculosis is currently responsible for more deaths annually than any other infectious disease, representing a significant global public health threat. Of growing concern is the rapid emergence of drug-resistant tuberculosis strains that do not respond to traditional antibiotic medicines.
To address this need for better tuberculosis medicines, this project will explore new strategies towards the development of novel small molecules that are highly potent against drug-resistant strains of the tuberculosis bacteria yet produce fewer side effects than existing treatments.
Additional components of this project include the development of unique photoactive molecular frameworks as warheads for photoaffinity labelling that will assist with both target identification and chemoproteomic experiments to deliver key insights that can be used to develop new antibiotics that have increased binding selectivity and improved safety profiles.
Eligible only for Australian or New Zealand Citizens or Permanent Residents. The project would be suitable for anyone with a strong background in synthetic organic chemistry and/or medicinal chemistry. Candidates should hold or expect to gain a first class degree and/or an appropriate Master’s level qualification (or their equivalent) and first author publication(s). Applicants whose first language is not English will be required to demonstrate proficiency in the English language (IELTS 6.5 or equivalent).
The project will be supervised by Dr Daniel Priebbenow (www.monash.edu/pharm/research/themes/medicinal-chemistry/priebbenow-group/home) in collaboration with other research teams at Monash University. The student will receive training in organic synthesis, photochemistry and medicinal chemistry. Transferable skills including scientific communication, time management, project management will also be developed through Faculty PhD training programmes, group meetings and conference attendance/presentations.
The successfully candidate will join a highly active research group of PhD students and researchers at the Monash Institute of Pharmaceutical Sciences in Parkville, Melbourne. The highly collaborative Institute comprises a range of chemistry- and biology-based research groups and is well equipped with synthesis and analytical equipment.
Please contact Dr Daniel Priebbenow (Email: email@example.com) for further information. Interested applicants (Eligible only for Australian or New Zealand Citizens or Permanent Residents) should provide details of their qualifications, including a CV, publications and a brief covering letter outlining their motivation and experience for the position before the 10th October 2022.